Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amylin Pharmaceuticals, a biopharmaceutical company engaged in discovery, development and commercialization of medicines, has reported revenues of $152.71m for the first quarter ended 31 March 2011, compared to $174.14m for the comparable period in 2010.
Subscribe to our email newsletter
The company has posted a net loss of $37.32m for the first quarter 2011, or $0.26 loss per diluted share, compared to net loss of $38.2m, or $0.27 loss per diluted share, for the comparable period in last year.
Operating loss was $29.08m, compared to $32.84 during the same period in the previous year.
Amylin Pharma Finance senior vice president and chief financial officer Mark Foletta said they remain focused on their longer-term target of generating sustainable positive operating cash flow.
Amylin Pharma president and CEO Daniel Bradbury said in the coming quarters, they will submit their reply to the Bydureon complete response letter, as well as completing their regulatory application for the use of metreleptin in patients with lipodystrophy.